INTERNATIONAL STEM CELL CORPORATION International Stem Cell Corporation Stock
Equities
ISCO
US4603782016
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.09 USD | -7.22% |
|
-9.55% | +45.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 8.18M | Sales 2023 | 7.79M | Capitalization | 496K |
|---|---|---|---|---|---|
| Net income 2022 | - | Net income 2023 | - | EV / Sales 2022 | 0.61 x |
| Net Debt 2022 | 3.53M | Net Debt 2023 | 2.59M | EV / Sales 2023 | 0.4 x |
| P/E ratio 2022 |
-4.35
x | P/E ratio 2023 |
-3.79
x | Employees | 29 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 27.91% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -7.22% | ||
| 1 week | -9.55% | ||
| Current month | -9.55% | ||
| 1 month | -10.00% | ||
| 3 months | +35.54% | ||
| 6 months | -18.18% | ||
| Current year | +45.16% |
1 week
0.09
0.10
1 month
0.060.12
Current year
0.050.13
1 year
0.050.17
3 years
0.050.80
5 years
0.001.20
10 years
0.0025.28
| Managers | Title | Age | Since |
|---|---|---|---|
Andrey Semechkin
CEO | Chief Executive Officer | 64 | 08-11-30 |
Russell Kern
DFI | Director of Finance/CFO | 38 | 08-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Kern
DFI | Director of Finance/CFO | 38 | 08-09-30 |
Paul Maier
BRD | Director/Board Member | 76 | 07-06-30 |
Andrey Semechkin
CEO | Chief Executive Officer | 64 | 08-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 0.09 | -7.22% | 102 |
| 24-05-03 | 0.097 | -11.01% | 970 |
| 24-05-02 | 0.109 | +9.55% | 14,007 |
Delayed Quote OTC Markets, May 06, 2024 at 01:19 pm EDT
More quotes
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Calendar
2024-05-15
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +45.16% | 720K | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- ISCO Stock